

S3 Table. The efficacy of PD-1/PD-L1 inhibitors monotherapy in advanced NSCLC patients

	Total (n=425)	With irAEs (n=127)	Without irAEs (n=298)	p-value
CR	1 (0.2)	1 (0.8)	0 (0)	
PR	99 (23.3)	46 (36.2)	53 (17.8)	
SD	210 (49.4)	67 (52.8)	143 (48.0)	
PD	115 (27.1)	13 (10.2)	102 (34.2)	
ORR	100 (23.5)	47 (37.0)	53 (17.8)	< 0.001
DCR	310 (72.9)	114 (89.8)	196 (65.8)	< 0.001

Values are presented as number (%). CR, complete response; DCR, disease control rate; irAEs, immune-related adverse events; NSCLC, non-small cell lung cancer; ORR, objective response rate; PD, progressive disease; PD-L1, programmed death-ligand 1; PD-1, programmed death-1; PR, partial response; SD, stable disease.